RegulationPriority Review (United States), Breakthrough Therapy (United States), Accelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), Conditional marketing approval (China)

Structure/Sequence

Molecular FormulaC26H23N7O2

InChIKeyWDENQIQQYWYTPO-IBGZPJMESA-N

CAS Registry1420477-60-6

161

Clinical Trials associated with Acalabrutinib

NCT07024706

/ Not yet recruitingPhase 2

The MAVRiC Study: A Phase II Study of Disease Risk Mutation Guided Finite Duration Acalabrutinib Plus Venetoclax for Relapse in CLL/SLL After First-line Finite Covalent BTKi Plus BCL2i Combination, With or Without Obinutuzumab

This study will evaluate the efficacy and safety of finite-duration acalabrutinib plus venetoclax therapy in patients with relapsed CLL or SLL, and have previously responded to first line (1L) cBTKi + BCL2i therapy (± obinutuzumab) and maintained a response for at least two years post-treatment.

Start Date30 Sep 2025

Sponsor / Collaborator

AstraZeneca PLC

[+2]

NCT06520098

/ Not yet recruitingPhase 2IIT

Benefit of Venetoclax Addition ("Benefit VA") in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

People who have chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) are often treated with ibrutinib, acalabrutinib, or zanubrutinib. These are pills that are taken by mouth. This type of pill is called "Bruton Tyrosine Kinase Inhibitor" or BTKi. Another treatment for CLL/SLL is a different pill called venetoclax.
The purpose of this study is to compare continuing the current treatment with BTKi alone, as long as it is working, to another arm of treatment which adds venetoclax to the current treatment (BTKi), for one year. After one year, both pills in this arm of treatment would be stopped and the participants will be closely monitored.

Start Date01 Jul 2025

Sponsor / Collaborator

VA Office of Research and Development

NCT06839872

/ WithdrawnPhase 2

BOSS: BTK Inhibitor Optimal Sequencing Study Phase II Open-label Single Arm Trial of Pirtobrutinib in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma After First-line Acalabrutinib Progression

To assess the efficacy and safety of pirtobrutinib in participants with CLL/SLL who have progressed on first-line treatment with acalabrutinib.

Start Date30 Jun 2025

Sponsor / Collaborator

AstraZeneca PLC

[+1]

100 Clinical Results associated with Acalabrutinib

100 Translational Medicine associated with Acalabrutinib

100 Patents (Medical) associated with Acalabrutinib

868

Literatures (Medical) associated with Acalabrutinib

01 Aug 2025·INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Acalabrutinib alleviates metabolic dysfunction–associated steatotic liver disease by regulating bile acid metabolism

Article

Author: Ye, Bingjue ; Zhou, Cheng ; Lou, Guohua ; Zheng, Min ; Wang, Yanbo ; Liu, Yanning ; Yang, Zhenggang ; Chen, Shiwei

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a global epidemic of chronic liver disease currently lacking effective treatment. Evaluating the therapeutic effects of existing drugs on MASLD is a time and cost-effective strategy. Bruton's tyrosine kinase (BTK) is an inflammatory signaling molecule playing an important role in the progression of MASLD. Aclabrutinib, a BTK inhibitor approved for treating mantle-cell lymphoma and chronic lymphocytic leukemia, has not been investigated for its potential to treat MASLD. This study examined the therapeutic effects and mechanisms of aclabrutinib on MASLD using a high-fat diet-induced mouse model. Results demonstrated significant alleviation of pathological parameters associated with MASLD upon administration of aclabrutinib. TSE PhenoMaster results revealed that aclabrutinib increased energy expenditure in mice. Furthermore, aclabrutinib upregulated the expression of genes associated with thermogenesis and lipolysis in adipose tissues. Additionally, it inhibited the transcription of genes related to lipid absorption in the small intestine and liver, while increasing the expression of hormone-sensitive lipase, hepatic nuclear factor 4 alpha and fibroblast growth factor 21 in the liver. Further analysis indicated that aclabrutinib promoted the alternative pathway of bile acid synthesis while restoring gut microbiota homeostasis. The altered bile acid profiles upregulated G protein-coupled bile acid receptor 1 expression in adipose tissues as well as vitamin D receptor expression in liver and small intestine. Our findings suggest that by regulating bile acid metabolism and gut microbiota, aclabrutinib may promote thermogenesis and lipolysis, thereby alleviating MASLD. This study provides novel insights into clinical applications targeting BTK for treating MASLD.

01 Jul 2025·PHARMACOLOGICAL RESEARCH

Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs): A 2025 update

Review

Author: Roskoski, Robert

Because aberrations of protein kinase activity play causal roles in several human diseases, this family of enzymes is one of the most important drug targets of the 21st century. Of the 88 protein kinase antagonists that are approved by the FDA, eleven of them form irreversible covalent complexes with their target enzymes. The clinical efficacy of ibrutinib, a Bruton tyrosine kinase blocker, in the treatment of mantle cell lymphoma following its 2013 approval helped to overcome a general bias against the development of irreversible drug inhibitors. Other approved targeted covalent inhibitors include acalabrutinib and zanubrutinib, which also block Bruton tyrosine kinase. Afatinib, dacomitinib, lazertinib, mobocertinib, and osimertinib inhibit members of the epidermal growth factor receptor family (ErbB1/2/3/4) and are used in the treatment of non-small cell lung cancers. Neratinib inhibits ErbB2 and is used in the management of ErbB2/HER2-positive breast cancer. Futibatinib blocks the fibroblast growth factor receptor family and is prescribed for the treatment of cholangiocarcinoma while ritlecitinib, which inhibits JAK3, is used in the management of alopecia areata. The eleven drugs considered in this review have a common mechanism of action involving the addition of a protein cysteine thiolate anion (proteinS:) to an acrylamide or an acrylamide-like derivative producing a thioether. The development of targeted covalent inhibitors is gaining acceptance as a valuable component of the medicinal chemist's toolbox and has made a significant impact on the development of protein kinase antagonists and receptor modulators.

01 Jul 2025·BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Assessment of ethnic differences in pharmacokinetics and clinical responses of acalabrutinib between Chinese and White patients with B‐cell malignancies

Article

Author: Ma, Peiming ; Yao, Tingting ; Ding, Junjie ; Li, Yunfei ; Sharma, Shringi ; Xu, Qianwei

Abstract:

Aims:

The aim of this study was to assess differences between Chinese and White patients in pharmacokinetics (PK) of, and clinical response to, acalabrutinib and its pharmacologically active major metabolite, ACP‐5862, to support recommended dosing in Chinese patients with B‐cell malignancies.

Methods:

A population pharmacokinetic (pop‐PK) analysis was conducted to integrate data from a Chinese and a Japanese study into the existing model. The effect of race (East Asian vs. non‐East Asian) on acalabrutinib and ACP‐5862 PK parameters was assessed. The relationships between model‐predicted exposures (e.g., acalabrutinib area under the plasma concentration–time curve for 24 h at steady‐state [AUC24h,ss]) and best overall response and safety outcomes were investigated in Chinese patients and the overall population.

Results:

The pop‐PK analysis included 686 patients with B‐cell malignancies (Chinese, n = 105; Japanese, n = 6). A two‐compartment model adequately described the PK profiles of acalabrutinib and ACP‐5862 for Chinese patients. East Asian race was a statistically significant covariate on relative bioavailability and apparent volume of the peripheral compartment of acalabrutinib, showing 28% higher PK exposures in Chinese patients. The exposure–efficacy analysis showed that efficacy plateaued in Chinese patients with 100 mg twice‐daily dosing while the exposure–safety analysis indicated a flat relationship of acalabrutinib AUC24h,ss with grade ≥2 or ≥3 adverse events in both Chinese patients and the overall population with 100–400 mg daily doses.

Conclusions:

Higher PK exposure was observed in Chinese patients vs. White patients but did not indicate a safety concern based on exposure–response relationships. The results supported using the 100 mg twice‐daily dosing regimen in Chinese patients.

226

News (Medical) associated with Acalabrutinib

09 Jun 2025

·www.pharmaceutical-technology.com

EC approves AstraZeneca’s acalabrutinib combo for CLL

AstraZeneca’s Calquence approval decision follows a positive opinion from the Committee for Medicinal Products for Human Use. Credit: Elzbieta Krzysztof/Shutterstock. The European Commission (EC) has approved a fixed-duration regimen of AstraZeneca’s Bruton’s tyrosine kinase (BTK) selective inhibitor, Calquence (acalabrutinib) plus venetoclax, with or without obinutuzumab, to treat adults with previously untreated chronic lymphocytic leukaemia (CLL). This decision follows a positive opinion from the Committee for Medicinal Products for Human Use and is based on outcomes from the pivotal Phase III AMPLIFY trial. This trial demonstrated that 77% of subjects treated with Calquence and venetoclax combo and 83% of those who received the therapy along with venetoclax and obinutuzumab remained progression-free after three years. Calquence combined with venetoclax showed a 35% decrease in disease progression or mortality risk compared to chemoimmunotherapy. Calquence’s safety and tolerability were found to be consistent with the known safety profile, with no safety issues observed. Based on the Phase III outcomes, regulatory applications for these regimens are being reviewed in several countries. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence AstraZeneca oncology haematology business unit executive vice-president Dave Fredrickson stated: “Today’s approval brings a new fixed-duration treatment option to patients with previously untreated CLL across Europe. “Calquence plus venetoclax is the first and only all-oral combination treatment option with a second-generation BTK inhibitor approved in the EU and provides patients and their physicians more flexibility in managing this incurable blood cancer.” Calquence is currently approved for the treatment of chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL) in Japan, the US, China, and for CLL in the European Union (EU) and many other areas. It was also approved for previously untreated mantle cell lymphoma (MCL) in Europe , the US and other locations, and for treating adults with MCL after a minimum of one previous therapy in China and other countries. Calquence is part of an extensive clinical development programme, under assessment both as a monotherapy and in conjunction with standard-of-care chemoimmunotherapy for multiple B-cell blood cancers, including diffuse large B-cell lymphoma, MCL and CLL. Pharmaceutical Technology Excellence Awards - Have you nominated? Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact . This is your chance to showcase your achievements, highlight industry advancements , and gain global recognition . Don't miss the opportunity to be honoured among the best - submit your nomination today! Nominate Now

Clinical ResultPhase 3ImmunotherapyDrug ApprovalBiosimilar

06 Jun 2025

·firstwordpharma.com

AstraZeneca's Calquence combo wins first-line CLL approval in EU

The European Commission on Friday approved a fixed-duration regimen of AstraZeneca's Calquence (acalabrutinib) in combination with Roche's BCL-2 inhibitor Venclyxto/Venclexta (venetoclax), with and without Gazyvaro/Gazyva (obinutuzumab), as a front-line treatment for chronic lymphocytic leukaemia (CLL).The EU green light aligns with prescribing trends for the BTK inhibitor in the US, where it is widely used in the first-line setting, especially for CLL patients with cardiovascular comorbidities (see – Spotlight On: BTK inhibitors move towards fixed-duration combos in CLL)."Calquence plus venetoclax is the first and only all-oral combination treatment option with a second-generation BTK inhibitor approved in the EU and provides patients and their physicians more flexibility in managing this incurable blood cancer," commented Dave Fredrickson, AstraZeneca's EVP, oncology haematology business unit, in a company release. Reducing risk of deathThe approval follows a positive opinion handed down by the European Medicines Agency's drug advisory panel in April for the first-line Calquence combo. The decision was supported by results of the Phase III AMPLIFY trial, presented at the American Society of Hematology (ASH) meeting in December.After a median 41 months of followup, Calquence plus Venclyxto cut the risk of progression or death by 35% versus chemoimmunotherapy, achieving the primary endpoint. Adding Gazyvaro to the combination reduced the risk by 58%. Median progression-free survival wasn't yet reached for either experimental group, compared to 47.6 months for chemoimmunotherapy.The readout generated enthusiasm among US haematologists and oncologists, with 85% of respondents to a FirstWord poll reporting being at least somewhat impressed with the data, and more than half calling the all-oral, fixed-duration regimen highly promising (see – Physician Views Results: New data AMPLIFY Calquence's strong standing among doctors treating CLL).However, key opinion leaders (KOLs) who spoke with FirstWord for a report on the CLL landscape noted that AMPLIFY compared the Calquence combo against a somewhat outdated control arm of chemoimmunotherapy. The more practice-changing readout, according to KOLs, will likely be the ongoing Phase III MAJIC study assessing Calquence plus Venclyxto versus Venclyxto plus Gazyva, a fixed-term doublet that is becoming more widely used in frontline CLL.

Phase 3Clinical ResultDrug ApprovalASHImmunotherapy

06 Jun 2025

·www.astrazeneca.com

Fixed-duration Calquence-based regimens approved in EU for patients with chronic lymphocytic leukaemia in the 1st-line setting

A fixed-duration regimen of AstraZeneca’s Calquence (acalabrutinib) in combination with venetoclax, with or without obinutuzumab, has been approved in the European Union (EU) for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use and was based on positive results from the pivotal AMPLIFY Phase III trial, presented at the American Society of Hematology 2024 Annual Meeting and published in The New England Journal of Medicine.1 Results from the AMPLIFY trial showed 77% of patients treated with Calquence plus venetoclax and 83% of patients treated with Calquence plus venetoclax and obinutuzumab were progression free at three years, versus 67% of patients treated with standard-of-care chemoimmunotherapy (investigator’s choice of fludarabine-cyclophosphamide-rituximab or bendamustine-rituximab).1 Median progression-free survival (PFS) was not reached for either experimental arm versus 47.6 months for chemoimmunotherapy.1 Calquence plus venetoclax reduced the risk of disease progression or death by 35% compared to chemoimmunotherapy (hazard ratio [HR] 0.65; 95% confidence interval [CI] 0.49-0.87; p=0.0038). Calquence plus venetoclax with obinutuzumab demonstrated a 58% reduction in the risk of disease progression or death compared to chemoimmunotherapy (HR 0.42; 95% CI 0.30-0.59; p<0.0001).2 CLL is the most common type of leukaemia in adults. An estimated 27,000 people were diagnosed with CLL in the UK, France, Germany, Spain and Italy in 2024.3 Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany and investigator for the AMPLIFY trial, said: “For patients diagnosed with chronic lymphocytic leukaemia, this approval provides a new option in the first-line setting that may help to minimize long-term side effects and reduce drug resistance as they may occur with continuous treatment. A fixed-duration regimen is appealing to patients and helps with adherence during the treatment period.” Dave Fredrickson, Executive Vice President, Oncology Haematology Business Unit, AstraZeneca, said: “Today’s approval brings a new fixed-duration treatment option to patients with previously untreated chronic lymphocytic leukaemia across Europe. Calquence plus venetoclax is the first and only all-oral combination treatment option with a second-generation BTK inhibitor approved in the EU and provides patients and their physicians more flexibility in managing this incurable blood cancer." The safety and tolerability of Calquence was consistent with its known safety profile, and no new safety signals were identified. Regulatory applications for these regimens are currently under review in several countries based on the AMPLIFY results. Notes Chronic lymphocytic leukaemia (CLL) CLL is the most prevalent type of leukaemia in adults, with an estimated 40,000 people being treated for CLL in the first line in the US, UK, France, Germany, Spain, Italy, Japan and China in 2024.3 Although some people with CLL may not experience any symptoms at diagnosis, others may experience symptoms, such as weakness, fatigue, weight loss, chills, fever, night sweats, swollen lymph nodes and abdominal pain.4 In CLL, there is an accumulation of abnormal lymphocytes within the blood, bone marrow and lymph nodes. As the number of abnormal cells increases, there is less room within the marrow for the production of normal white blood cells, red blood cells and platelets.5 This could result in infection, anaemia and bleeding. B-cell receptor signalling through BTK is one of the essential growth pathways for CLL. AMPLIFY AMPLIFY is a randomised, global, multi-centre, open-label Phase III trial evaluating the efficacy and safety of Calquence in combination with venetoclax, with or without obinutuzumab, compared to investigator's choice of chemoimmunotherapy (fludarabine-cyclophosphamide-rituximab or bendamustine-rituximab) in adult patients with previously untreated CLL without del(17p) or TP53 mutation.6 Patients were randomised 1:1:1 to receive either Calquence plus venetoclax, or Calquence plus venetoclax with obinutuzumab for a fixed duration, or standard-of-care chemoimmunotherapy.6 Both the Calquence containing arms were administered for a fixed duration of 14 cycles (each 28 days), and the standard-of-care chemoimmunotherapy was for 6 cycles.6 The primary endpoint is PFS in the Calquence and venetoclax arm as assessed by an Independent Review Committee, and PFS in the Calquence plus venetoclax with obinutuzumab arm is a key secondary endpoint.6 Other key secondary endpoints include overall survival (OS) and undetectable measurable residual disease.6 The trial includes 27 countries across North and South America, Europe, Asia and Oceania.6 The AMPLIFY trial enrolled patients from 2019 to 2021, continuing through the COVID-19 pandemic.6 Calquence Calquence (acalabrutinib) is a second-generation, selective inhibitor of Bruton’s tyrosine kinase (BTK). Calquence binds covalently to BTK, thereby inhibiting its activity.8 In B-cells, BTK signalling results in activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis and adhesion. Calquence is approved for the treatment of chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL) in the US, Japan and China, and approved for CLL in the EU and many other countries. Calquence is also approved in combination with venetoclax, with or without obinutuzumab, as a fixed-duration treatment for CLL in the EU. Calquence is also approved for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) in the US, Europe and other countries. It is also approved for the treatment of adult patients with MCL who have received at least one prior therapy in China and several other countries. Calquence is not currently approved for the treatment of MCL in Japan. As part of an extensive clinical development programme, Calquence is currently being evaluated as a single treatment and in combination with standard-of-care chemoimmunotherapy for patients with multiple B-cell blood cancers, including CLL, MCL and diffuse large B-cell lymphoma. AstraZeneca in haematology AstraZeneca is pushing the boundaries of science to redefine care in haematology. Our goal is to help transform the lives of patients living with malignant, rare and other related haematologic diseases through innovative medicines and approaches that are shaped by insights from patients, caregivers and physicians. In addition to our marketed products, we are spearheading the development of novel therapies designed to target underlying drivers of disease across multiple scientific platforms. Our acquisitions of Alexion, with expertise in rare, non-malignant blood disorders, and Gracell Biotechnologies Inc., pioneers of autologous cell therapies, expand our haematology pipeline and enable us to reach more patients with high unmet needs through the end-to-end discovery, development and delivery of novel therapies. AstraZeneca in oncology AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients. The Company's focus is on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyse changes in the practice of medicine and transform the patient experience. AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death. AstraZeneca AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca. Contacts For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here. References Matthew Bowden Company Secretary AstraZeneca PLC Oncology Corporate and financial

Clinical ResultImmunotherapyDrug ApprovalPhase 3Acquisition

100 Deals associated with Acalabrutinib

External Link

KEGG	Wiki	ATC	Drug Bank
D10893	Acalabrutinib	L01XE51	DB11703

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Mantle cell lymphoma recurrent	European Union	AstraZeneca AB	27 May 2025
Mantle cell lymphoma recurrent	Iceland	AstraZeneca AB	27 May 2025
Mantle cell lymphoma recurrent	Liechtenstein	AstraZeneca AB	27 May 2025
Mantle cell lymphoma recurrent	Norway	AstraZeneca AB	27 May 2025
Mantle cell lymphoma refractory	European Union	AstraZeneca AB	27 May 2025
Mantle cell lymphoma refractory	Iceland	AstraZeneca AB	27 May 2025
Mantle cell lymphoma refractory	Liechtenstein	AstraZeneca AB	27 May 2025
Mantle cell lymphoma refractory	Norway	AstraZeneca AB	27 May 2025
Small Lymphocytic Lymphoma	United States	AstraZeneca UK Ltd.	21 Nov 2019
Chronic Lymphocytic Leukemia	Canada	AstraZeneca Canada, Inc.	02 Oct 2019
Mantle-Cell Lymphoma	United States	AstraZeneca UK Ltd.	31 Oct 2017

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
ALK positive large B-cell lymphoma	Phase 3	Germany	AstraZeneca PLC	07 Jun 2023
Large B-cell lymphoma	Phase 3	Germany	AstraZeneca PLC	07 Jun 2023
Mediastinal large B-cell lymphoma	Phase 3	Germany	AstraZeneca PLC	07 Jun 2023
Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type	Phase 3	Germany	AstraZeneca PLC	07 Jun 2023
T-cell/histiocyte rich large B-cell lymphoma	Phase 3	Germany	AstraZeneca PLC	07 Jun 2023
Recurrent Chronic Lymphoid Leukemia	Phase 3	Germany	AstraZeneca PLC	19 Apr 2022
Diffuse Large B-Cell Lymphoma	Phase 3	United States	AstraZeneca PLC	08 Oct 2020
Diffuse Large B-Cell Lymphoma	Phase 3	China	AstraZeneca PLC	08 Oct 2020
Diffuse Large B-Cell Lymphoma	Phase 3	Japan	AstraZeneca PLC	08 Oct 2020
Diffuse Large B-Cell Lymphoma	Phase 3	Australia	AstraZeneca PLC	08 Oct 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO2025	Not Applicable	Chronic Lymphocytic Leukemia Bruton’s tyrosine kinase (BTK) inhibitor	-	Chemoimmunotherapy	zwlwcywmtj(btnfvwxwzm) = jxskmprwfq fmagfxprik (fkmmdueido )	Positive	30 May 2025
ASCO2025	Not Applicable	Chronic Lymphocytic Leukemia \| Small Lymphocytic Lymphoma	-	Acalabrutinib	xejhevjvle(qdqnuhlljp): HR = 0.22 (95% CI, 0.09 - 0.53), P-Value = 0.001 View more	Positive	30 May 2025
				Ibrutinib
ASCO2025	Not Applicable	Chronic Lymphocytic Leukemia \| Small Lymphocytic Lymphoma First line	454	Acalabrutinib	kwmitnwxcs(wngvnteeeo) = less common with acalabrutinib than with ibrutinib ugtunebqmo (mthlwaiuar ) View more	Positive	30 May 2025
				Ibrutinib
HOVON 159/REVEAL (EHA2025)	Phase 2	Recurrent Chronic Lymphoid Leukemia	44	Venetoclax-acalabrutinib	ndosqabqew(ionolrrigx) = 50% cmsrnkaohp (qazojqmlvl ) View more	Positive	14 May 2025
NCT02972840 (ECHO, EHA2025)	Phase 3	Mantle-Cell Lymphoma blastoid/pleomorphic histology	-	Rituximab-Bendamustine	roxzmsjtiu(jcfholvuvf) = yvjmldqzvh ilqiiluhnh (arqbgjwfom ) View more	Positive	14 May 2025
				Placebo+BR	roxzmsjtiu(jcfholvuvf) = ylxzxveeeu ilqiiluhnh (arqbgjwfom ) View more
PF945 (EHA2025)	Phase 1	Refractory Central Nervous System Lymphoma IRF4 mutation	17	Rituximab	eisfuxsgam(qkgeigzrkb) = Treatment-related adverse events occurred in 14 patients (82%), with 59% experiencing grade 3/4 events, mainly neutropenia, skin reactions, and transaminitis gvdokvvntm (jfofwucjvn )	Positive	14 May 2025
NCT02972840 (ECHO, EHA2025)	Phase 3	Mantle-Cell Lymphoma MRD positive	-	Bendamustine-Rituximab	mbaxtxxmqc(ueilmmagfy) = rmxeabvrxh spiegagmzl (msvrxhfsbz ) View more	Positive	14 May 2025
				Placebo	mbaxtxxmqc(ueilmmagfy) = elmoqrlxqh spiegagmzl (msvrxhfsbz ) View more
NCT05820841 (ARCHED/GLA 2022-1, EHA2025)	Phase 3	Large B-cell lymphoma	101	R-miniCHOP	vhgvlzazll(gsduqhfcmh) = fyscjpvdar qgarodjqwa (pldmpzlzqm ) View more	Positive	14 May 2025
				R-miniCHOP + Acalabrutinib	vhgvlzazll(gsduqhfcmh) = svltygsilp qgarodjqwa (pldmpzlzqm ) View more
PB2626 (EHA2025)	Not Applicable	Chronic Lymphocytic Leukemia \| Small Lymphocytic Lymphoma	454	Acalabrutinib	oodzbvhsat(kypoluprpy) = qchcjyvixr jouxicstps (qtpchpqgun ) View more	Positive	14 May 2025
				Ibrutinib	oodzbvhsat(kypoluprpy) = zmmlmglvcg jouxicstps (qtpchpqgun ) View more
NCT03836261 (AMPLIFY, EHA2025)	Phase 3	COVID-19 \| Chronic Lymphocytic Leukemia	867	Acalabrutinib-Venetoclax Combination	yzahtwcqfv(febzfoxfvb) = Death due to COVID-19 any time during the trial occurred in 10 (3.4%), 25 (8.7%), and 21 (7.2%) pts in the AV, AVO, and FCR/BR arms, respectively (of which 80.0%, 60.0%, and 33.3%, respectively, occurred during the tx-emergent period); 5/10, 9/25, and 7/21, respectively, were aged >65 y. edwnirutok (zmttiurckd )	Positive	14 May 2025
				Obinutuzumab

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis